Introduction
Frozen erythrocytes, thrombocytes, lymphocytes and hematopoietic progenitor cells (from peripheral blood as well as from bone marrow) are being used for various diagnostic and therapeutic purposes [reviews in e.g. [1] [2] [3] . A variety of cell-specific cryopreservation protocols have evolved so far. The methods differ with regard to i) cell concentrations, ii) protective solutions used (cryoprotectants and their concentrations), iii) temperature-time histories (TTH) during cooling and re-warming, and iv) storage temperature. Additionally, some of the cryoprotectants are not well tolerated clinically in the concentrations required for cryopreservation (e.g. dimethyl sulfoxide (DMSO) for platelets) or lead to an osmot ically induced lysis of the cryoprotectant-loaded cells when transfused into an isotonic individual organism (e.g. glycerol for erythrocytes). In these cases, a washing procedure is required after thawing to remove the cryoprotective additive prior to the application/transfusion.
Erythrocytes

Clinically Applied Methods Using Glycerol
In principle, three different methods have been established for routine clinical use of frozen red cells (RBC) [4] ; these are: i) The Huggins [5] technique utilizes ~40% [wt/v] glycerol as the cryoprotective additive. Prior to transfusion the glycerol is removed by reversible agglomeration of the RBC using nonionic sugar solutions. Initially used by many hospitals, this procedure is rarely used now because of unavailability of required equipment and disposable supplies. ii) The 'high glycerol slow cooling technique' according to Meryman and Hornblower [6] utilizes ~40% [wt/v] glycerol and washing with concentrated salt solutions prior to transfusion. This is the dominant method in use in the USA [for details see 7, 8] . iii) The 'low glycerol-rapid cooling technique' according to Rowe [9, 10] 
Methods Using Macromolecular Additives
The utilization of macromolecular cryoprotectants is an alternative approach to using glycerol for cryopreservation of erythrocytes. Watersoluble, cryoprotective macromolecules such as albumin, dextrans, modified gelatin, polyvinylpyrrolidone (PVP), polyethylene oxide (PEO), polyethylene glycol (PEG) and hydroxyethyl starches (HES) exhibit the principal advantage of not entering into the cells. This property significantly facilitates their removal after thawing. In the case of emergencies, this step could be omitted if the additive, e.g. albumin, dextrans, modified gelatin or HES, is biodegradable and tolerated by the human organism.
Cryopreservation with Hydroxyethyl Starch
Early studies on macromolecular cryoprotectants go back to Rinfret and coworkers [12] who utilized PVP successfully for freezing erythrocytes. In 1967 Knorpp and co-workers [13] described the successful cryopreservation of human RBC using HES and liquid nitrogen (LN2). Comparing the efficacy of HES to that of PVP, they preferred the colloid HES to PVP as the latter is retained to a considerable extent in the recipient (as are PEO and PEG). Moreover, in the case of hypovolemia, albumin, dextrans, modified gelatins and HES are often transfused to serve as blood volume substitutes. After several in vitro investigations and optimizations of the original HES procedure [14, 15] and after in vivo experiments in dogs, Sputtek and coworkers [16] conducted a successful in vivo study including seven healthy volunteers. They subsequently performed a systematic clinical trial in patients [17] . A detailed description of the method for the clinical application can be found in [8] , and a review of the development of the procedure in [18] . Nota bene: The patented freezing container ( fig. 1 [19] ) which must be used has a wall thickness of 2 mm. The exterior is pasted with a microporous textile tape to improve the heat transfer during the cooling process in boiling LN2. the initial cooling process. Please note that you will not be able to reproduce our results when not using the patented freezing container. Rapid thawing is needed as well: This can be achieved by using a shaking water bath with a pouch ( fig. 2  [8] ). The reason is that the composition of the cell suspension (e.g. hematocrit, HES concentration, electrolyte content), sample thickness, geometry and cooling rate are interdependent: A change in one of these parameters will lead to a less favorable result. Based on the work published by Robson [20] , Thomas and coworkers [21, 22] have developed a modified procedure for the freezing of RBC using HES. The major differences compared to our procedure are: i) no pre-freeze washing, ii) different HES modification, iii) lower HES concentration, iv) higher electrolyte concentration, v) higher hematocrit, vi) larger freezing bag, vii) smaller sample thickness, viii) smaller volume, ix) higher viscosity, x) different freezing container, and xi) uncontrolled thawing. Unfortunately, because of high viscosity, they must dilute or wash out the HES prior to transfusion because of poor flow rate of the concentrated HES-erythrocyte mixture.
As we have pointed out, it is essential to remove white cells and platelets prior to freezing. Thomas et al. [22] have speculated that the contents of the white cells and platelets are highly thromboplastic. As these cells are destroyed on freezing, thereby liberating their contents into the HES/RBC mixture, failure to filter could cause a disseminated intravascular coagulopathy when the RBC are subsequently thawed and transfused without post-thaw washing. Cryobiological researchers and clinical colleagues interested in our HES method for freezing erythrocytes have posed questions regarding the nature of HES and where it can be obtained. The following 2 paragraphs address some of these issues.
Structure of HES
HES is a modified natural polymer of branched amylopectin (one of the two components of starch, the other component is the linear amylose). Its physical and chemical characteristics are mainly defined by i) the degree of hydroxyethylation (DS), i.e. replacement of hydroxyl groups of the anhydroglucose units by hydroxyethyl groups) and ii) the molecular weight distribution. Whereas native starch is hardly watersoluble, hydroxyethylation increases water solubility. DS is determined by measuring the number of substituted anhydroglucose units and dividing this number by the total number of anhydroglucose units in the molecule. The molar substitution (MS) is calculated by measuring the total number of hydroxyethyl groups present and dividing this by the total number of anhydroglucose units. DS and MS are not the same, but they are often incorrectly used interchangeably in the literature. As hydroxyethylation can occur at carbon positions 2, 3 or 6 of the anhydroglucose unit, depending of the manufacturing process, the substitution pattern can vary greatly. HES molecules show a great polydispersity (in contrast to other cryoprotectants such as glycerol and DMSO, which have molecular weights of 92.09 g/mol and 78.13 g/mol, respectively. The molecule sizes of HES usually follow a sort of bell-shaped distribution, ranging from some thousand g/mol to over a million g/mol. Consequently 'the molecular weight' can by regarded as an 'average' molecular weight only. There are two ways for the calculation: i) arithmetic mean, i.e. total weight of all molecules dived by the number of molecules (Mn) and weight averaged mean (Mw). For example, an HES specified as '450/0.7' should be an HES with an Mw of 450,000 g/mol and an MS of 0.7 (i.e. 70 hydroxyethyl groups per 100 anhydroglucose units of the polymer). A comprehensive overview on the structure of HES can be found in Banks et al. [23] . Of major importance is that HES, a plasma volume expander, is metabolized by the body and excreted unlike some other macromolecules (e.g. PEO, PVP).
HES Solutions
For historical and marketing reasons, predominantly slowly degradable, high MW HES (450/0.7) is available in the USA. In Europe, a large variety of HES solutions is available, dominated by medium MW, easily degradable HES (200/0.5) [24] . The optimized HES solution used in our clinical trials with patients (KryoHAES ® , manufactured by Fresenius, Bad Homburg, Germany, according to our specifications) had an HES concentration of 23% (wt/wt) which equals 25% (wt/v). This is higher than the 3% (wt/v), 6% (wt/v) or 10% (wt/v) solutions available for clinical use. The sodium chloride concentration of 60 mmol/l was lower than the 'standard' 155 mmol/l. The average MW and the DS were 200,000 g/mol and 0.5, respectively. Although it is commercially not available at present, it can be prepared from dry HES powder or commercially available HES solutions after dialysis and freeze drying [25, 26] . The dry substance can be dissolved in distilled water and the appropriate amount of sodium chloride has to be added. and the electrolyte content is adjusted to isotonicity (mostly by adding sodium chloride). The solutions available for volume replacement may contain various amounts of LMWI, these may differ from one HES modification to the other, and sometimes even from one lot to the next from the same manufacturer. If this is not taken into account, it will be difficult to reproduce the work.
Determination of RBC Recovery/Viability
The determination of cell recovery/viability after thawing in the presence of HES poses a problem. HES coats the surface of the erythrocytes and may provide a scaffolding for damaged membranes so that some cells appear intact, though they will rupture if diluted with isotonic saline. Viability after thawing, in terms of 'saline stability', can be determined as follows [14] : 250 µl of the RBC suspension is diluted 40-fold in a buffered isotonic saline solution. After 30 min the suspension is separated into a supernatant (destroyed RBC) and sediment (intact RBC) by centrifugation. Saline stability is then calculated using:
where HbT corresponds to the total hemoglobin and HbS to the hemoglobin in the supernatant. The determination of the 2 hemoglobin concentrations can be performed spectrophotometrically at 546 nm using Drabkin's solution. A correction for the hematocrit is not required, as the volume fraction of erythrocytes after 40-fold dilution is less than 2%. Plasma stabilities (i.e. when plasma is used as diluent in the test instead of isotonic saline) may be slightly higher than saline stabilities because plasma factors allow a few very slightly damaged cells to recover. In the presence of HES (and other macromolecular cryoprotectants!) the post-thaw recovery of intact cells, determined by simply spinning down the suspension without any dilution and measuring the percentage of 'free' hemoglobin, should not be used as a quality control procedure because the result is misleading, irrespective of the hematocrit being taken into consideration or not.
Thrombocytes
Since the first reported attempt in 1956 to stop thrombocytopenic bleeding by the infusion of previously frozen platelets by Klein [27] , a broad variety of in vitro and in vivo studies on cryopreserved platelets have been published. Djerassi et al. [28] in 1966 were the first to report on the use of 5% DMSO and cooling at 1 C°/min for successful cryopreservation and transfusion of human platelets. As no removal of DMSO after thawing was performed, the recipients suffered from problems arising from infusion of this substance. The introduction of a post-thaw washing procedure by Lundberg et al. [29] helped to overcome the symptoms of nausea, vomiting, local vasospasm and a garlic-like odor and taste. The most widely used method for the cryopreservation of platelets is a '10% DMSO-slow cooling' method tested clinically by Schiffer [3, 8, 30, 31] while another approach is a 'low glycerol/glucose-intermediate cooling' method described by Dayian and Rowe in 1976 [1, 32] . HES-cryopreserved platelets (frozen in the presence of 4% (wt/v) HES at 1 °C/ min), turned out to be hemostatically effective when using a 4% HES method [33] . Optimum results can only be achieved when increasing the cooling rate from 1 °C/min as described by Choudhury [33] to 15 ± 5 °C/min and reducing the sodium chloride concentration in the cryoprotective solution from isotonic to 120 mmol/l [8, 34] . When comparing the optimized HES method to Schiffer's technique [30, 31] , both protocols turned out to be highly effective regarding the post-thaw numerical platelet recovery (approximately 90%). However, functional in vitro parameters showed that the DMSO-protected frozen platelets were inferior to fresh controls but superior compared to the HES-protected ones [35] .
Lymphocytes
The use of cryopreserved mononuclear cells (which includes lymphocytes) is well established and a routine procedure for clinical laboratory testing. Cohen and Rowe [36] were the first to report on detection of leukoagglutinins with frozen lymphocytes for transfusion compatibility, a forerunner of tissue typing plates in common use for detection of HLA (human leukocyte antigen) antibodies. Today frozen lymphocytes are Cryopreservation of Erythrocytes, Thrombocytes, and Lymphocytes used for various diagnostic purposes, e.g. HLA typing, detection of HLA antibodies in patients on waiting lists for organ/ bone marrow transplantations and mixed lymphocyte reactions/cultures. They are also of interest with respect to lookback procedures in transfusion medicine or diagnosis in patients. The methods for freezing mononuclear cells reported in the literature vary from one author to another [1] [2] [3] . Recently, there is a growing clinical interest in cryopreserved lymphocytes for the supplemental treatment of patients after blood stem cell transplantation making use of the 'graft-versusleukemia' effect in the case of relapse. Usually, those peripheral donor lymphocytes are frozen according to methods which are more or less modifications of a technique which was first described for bone marrow by Ashwood-Smith [37] in 1961 using 10% DMSO. During cooling, the heat is removed either by computer-controlled and LN2-operated machines or in mechanical (-80 °C) refrigerators. Cryopreserved autologous and homologous blood stem cells -which are mononuclear cells as well -have become a 'standard' blood component for the treatment of several malignant diseases. Stiff and co-workers [38] have reported that the addition of 6% HES reduced the 'original' concentration of DMSO (10%) by one half. Optimum results for peripheral blood stem cells can be obtained when using cooling rates between 1 and 5 °C/min and at least 5% DMSO are present [39] . A detailed review of the various procedures for hematopoietic stem cells (in German) can be found elsewhere [40] . If mononuclear cells are to be frozen for laboratory purposes, cell concentrations may range from 0.5 × 10 6 to 50 × 10 6 /ml, the most frequently used medium is RPMI 1640 supplemented with human or fetal calf serum or plasma, and the cryoprotectant of choice is 5-10% DMSO. Cooling is performed in 1 or 2 ml vials at 1-2 °C/min down to a temperature of -30 °C or less by means of a programmable LN2-operated freezer, whereas thawing is usually performed in a water bath of 37°C . Numerical recoveries reported vary from 60 to 90%. We believe that cooling rates at temperatures below -40 °C are not as critical as in the upper temperature region (i.e. above -40 °C) and can be increased up to 10 °C/min to save time. Additionally, we do not think that a programmable LN2-operated freezer is always required to generate the appropriate cooling rate: -80 °C refrigerators may be suitable as long as provision is taken (e.g. by using card board insulations) that the cooling rate in the upper temperature region does not exceed 5 °C/min. It is best to document the cooling rate of 1-5ºC/min with a suitable temperature recorder. For long-term storage (i.e. months or years), however, we recommend liquid nitrogen LN2 (-196 ºC) or the vapor (≤ -165 ºC). In any case temperatures well below -123 °C are needed, which is the glass transition temperature of maximally freeze concentrated aqueous DMSO solutions [41] . However, storage for a few days or weeks in -80 °C freezers may also be acceptable but prolonged storage (months or years) requires lower temperatures.
Granulocytes
There have been publications in the past which claim the successful cryopreservation of granulocytes [reviews in e.g. 42, 43] . Despite reports appearing now and then in the newer literature (mostly as abstracts), it is our opinion that no clinically suitable method for the preservation of granulocytes has been found. The huge variation of the in vitro results shows how cumbersome the viability assays are, and how unsuitable they will be to predict anything that is going to happen in vivo. Membrane integrity tests (i.e. staining tests, often referred to as 'viability tests') measure only a conditio sine qua non (i.e. an intact cell membrane). Mature granulocytes are end stage cells designed to break down and liberate their lysosomes and lysosomal enzymes causing cell destruction. However, what is the meaning of these results if tests measuring typical granulocytic functions (e.g. chemotaxis, bactericidal activity) fail to detect any significant activity? Takahashi and co-workers [44] have proposed some explanations why granulocytes are so unrewarding regarding their cryopreservation. Already at temperatures below -5 °C without the formation of ice, a significant loss of function can be observed. This could be prevented by the addition of DMSO, whereas glycerol failed to show this effect. Because of their limited osmotic tolerance (already a two-fold increase compared to isotonicity caused a significant loss of function), they are highly susceptible to the electrolyte enrichment taking place during ice formation. Granulocytes also showed a limited tolerance to hypotonic stress which may occur upon thawing.
